治療診斷學市場報告：趨勢、預測和競爭分析（至 2030 年）

治療診斷學和預測

全球治療診斷學市場的未來充滿希望，腫瘤學和非腫瘤學市場充滿機會。到 2030 年，全球治療診斷學市場預計將達到 55 億美元，2024 年至 2030 年複合年成長率為 17.3%。該市場的主要驅動力是癌症盛行率的增加、臨床試驗數量的增加以及對精準醫療的認知和採用的不斷提高。

• 在放射性同位素類別中，Lucintel 預計，由於鎦-177 產品的可用性和採用率不斷增加，鎦-177 在預測期內將出現最高成長。
• 從應用來看，腫瘤學仍然是一個很大的領域。
• 按地區分類，預計北美在整個預測期內仍將是最大的地區。這是由於高效成像技術的日益採用，以及該地區對精準醫療的日益關注。

治療診斷學市場的策略性成長機會

治療診斷學市場在多種應用中提供了各種策略成長機會。透過利用這些機會，我們可以擴大治療診斷學治療的領域並提高其影響。

• 腫瘤學應用：擴大治療診斷學在腫瘤學中的應用，特別是難以治療的癌症，可以解決未滿足的醫療需求，並透過強化和高效的治療來推動市場成長。
• 心臟病學：循環系統領域治療診斷學解決方案（例如心肌灌注造影）的發展開拓了新的市場領域，並增強了心血管疾病的診斷和治療。
• 神經病學：在神經病學中，治療診斷學具有巨大的發展潛力，它可以提供準確的診斷和治療，特別是在神經退化性疾病的影像和治療方面。
• 感染疾病：將治療診斷學擴展到結核病和病毒感染疾病等感染疾病，可以支持癌症的早期發現並促進癌症的早期治療，從而開闢了傳統腫瘤學之外的一系列應用領域。
• 農村醫療保健服務：使用行動裝置和遠端醫療將治療診斷學產品引入農村和服務不足的地區可以減少醫療保健差距，同時擴大市場範圍。

總之，這些趨勢預示著策略性成長前景，將推動各個醫學專業（尤其是放射學）的創新。透過滿足多樣化的醫療需求，市場可以實現永續成長，並對全球健康產生更大的影響。

治療診斷學市場的促進因素與挑戰

各種技術、經濟和監管因素正在影響治療診斷學市場。了解這些市場促進因素和挑戰對於成功駕馭市場並實現永續成長至關重要。

推動治療診斷學市場的因素是：

1.技術進步：治療診斷學製造技術、診斷影像方法、標靶治療等方面的創新正在提高其有效性並推動市場擴張。

2.癌症發生率上升：全球癌症患者數量的增加推動了對治療診斷學等標靶治療方法的需求，擴大了該領域使用的放射性同位素的市場。

3. 政府支持：政府透過監管激勵和融資加大對核子醫學和精準腫瘤學發展的支持，支持放射性同位素產業的成長。

4. 醫療保健全球化：全球醫療合作正在擴大治療診斷學治療的可近性，特別是在開發中國家。

5. 患者對個人化醫療的需求：患者對個人化、微創治療的需求不斷增加，推動了治療診斷學的採用，放射治療學提供了量身定做的治療方案。

治療診斷學市場面臨的挑戰是：

1. 生產成本高：生產放射性同位素和開發放射腫瘤藥物的高成本限制了可負擔性和可近性，對市場成長帶來了挑戰。

2.核准障礙：對放射性材料的核准和安全處理的嚴格監管要求可能會延遲新治療方法的推出。

3. 供應鏈挑戰：半衰期短和生產設施有限可能導致供不應求和無法獲得治療方法。

總之，儘管面臨高製造成本和監管障礙等挑戰，但治療診斷學市場仍受到技術進步和個人化醫療需求不斷成長的推動。應對這些因素對於市場相關人員實現持續成長並為患者提供創新治療至關重要。

目錄

第1章執行摘要

第2章全球治療診斷學市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 市場趨勢及預測分析（2018-2030）

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球治療診斷學市場趨勢（2018-2023）與預測（2024-2030）
• 全球治療診斷學市場：依放射性同位素分類
  • 碘131
  • 碘123
  • 鎵68
  • 鎦177
  • 18F配備Y-90
  • 其他
• 全球治療診斷學市場：按方法
  • 標靶治療
  • 針對性診斷
• 全球治療診斷學市場：依應用分類
  • 瘤
  • 除腫瘤外

第4章 各地區市場趨勢及預測分析（2018-2030）

• 全球治療診斷學市場：按地區
• 北美治療診斷學市場
• 歐洲治療診斷學市場
• 亞太地區放射治療診斷學市場
• 其他地區治療診斷學市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球治療診斷學市場成長機會：按放射性同位素
  • 全球治療診斷學市場成長機會：依方法
  • 全球治療診斷學市場成長機會：依應用分類
  • 全球治療診斷學市場成長機會：按地區
• 全球治療診斷學市場的新興趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球治療診斷學市場的產能
  • 全球治療診斷學市場的企業合併
  • 認證和許可

第7章主要企業簡介

• Novartis
• Bayer
• Progenics Pharmaceuticals
• Telix Pharmaceuticals Limited
• ITM Radiopharma
• Life Molecular Imaging
• RadioMedix

Radiotheranostic Trends and Forecast

The future of the global radiotheranostic market looks promising with opportunities in the oncology and non-oncology markets. The global radiotheranostic market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 17.3% from 2024 to 2030. The major drivers for this market are the increasing prevalence of cancer, the rising number of clinical trials, and the growing awareness and adoption of precision medicines.

• Lucintel forecasts that, within the radioisotope category, lutetium-177 is expected to witness the highest growth over the forecast period due to the increasing availability and adoption of lu-177 products.
• Within the application category, oncology will remain the larger segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the increasing adoption of efficient imaging technologies along with a growing inclination towards precision medicine in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radiotheranostic Market

Emerging trends in the radiotheranostics market are reshaping its future applications and dynamics:

• Precision Oncology: One of these trends is precision oncology, which uses radiotheranostics to target cancerous cells specifically, thus sparing healthy tissues from harm. It has become a cornerstone in modern cancer therapy, as it leads to better patient outcomes with fewer side effects.
• Globalization of Radioisotope Supply: This globalization ensures that the supply chains of radioisotopes are broader, leading to the availability of radiotheranostics therapies from any part of the world. Such efforts help mitigate potential shortages through the diversification of sources, ensuring consistent access to treatments globally.
• Integration with Digital Health: The introduction of AI and telemedicine among digital health technologies into radiotheranostics allows for better diagnosis and treatment planning. These innovations facilitate real-time monitoring and more accurate dosimetry, resulting in improved therapeutic outcomes.
• Expansion Beyond Oncology: The use of radiotheranostics has extended beyond oncology into cardiology, neurology, and infectious diseases. This creates new opportunities and expands the reach of these interventions.
• Patient-Centric Care Models: We are seeing the introduction of patient-centered care models based on personalized treatment plans and a multispecialty approach in the radiotheranostics field. These models are raising patient satisfaction levels and improving adherence to therapeutic protocols, which in turn enhances therapeutic outcomes.

In conclusion, these trends are revolutionizing radiotheranostics and making it a cornerstone of personalized medicine, gradually penetrating diverse fields of medicine.

Recent Developments in the Radiotheranostic Market

The radiotheranostics market is rapidly evolving, with several key developments shaping its growth and impact. These advancements have increased the effectiveness of treatment and expanded access to radiotheranostics therapies.

• Novel Radiation Theragnostic Agents: The development of new radiation theragnostic agents, specifically for prostate and neuroendocrine tumors, has resulted in more precise treatment and better outcomes for patients.
• Advanced Manufacturing Techniques: Advanced radioisotope production techniques have increased the availability of critical isotopes, such as Lutetium-177 and Gallium-68, which are used for cancer diagnosis, reducing costs and widening access to these therapies.
• Regulatory Approvals: Simplified regulatory proceedings in key markets have facilitated faster approval of radiotherapeutics, enabling swift access to novel treatments for patients.
• Strategic Collaborations: Strategic alliances between pharmaceutical companies, research institutions, and healthcare service providers aim to foster innovation while enhancing the development and delivery of radioactive therapeutics.
• Global Market Expansion: Growing investment in nuclear medicine infrastructure globally, coupled with the adoption of therapies in emerging markets, has necessitated global growth in radiotheranostics.

In conclusion, these key developments are strongly impacting the radiotheranostics market by fueling innovation, increasing access, and improving patient outcomes. As the market continues to grow, these changes will be instrumental in shaping its future.

Strategic Growth Opportunities for Radiotheranostic Market

A variety of strategic growth opportunities exist within multiple applications across the radiotheranostics market. Tapping into these opportunities can expand the sector and increase the influence of radiotheranostics therapies.

• Oncology Applications: Expanding radiotherapeutic applications for oncology, especially for hard-to-treat cancers, can address unmet medical needs and stimulate market growth through focused and efficient treatment.
• Cardiology: The development of radiotheranostics solutions in cardiology, such as for myocardial perfusion imaging, will open up new market areas and enhance the diagnosis and treatment of cardiovascular conditions.
• Neurology: In neurology, there is great potential for the growth of radiotheranostics, particularly with respect to imaging and treating neurodegenerative diseases, providing both accurate diagnostics and therapy.
• Infectious Diseases: Expanding radiotheranostics into infectious diseases, such as tuberculosis and viral infections, will assist in early detection and promote early cancer treatment, widening the scope beyond traditional oncology applications.
• Rural Healthcare Access: The use of mobile units or telemedicine to bring radiotheranostics into rural and underserved areas would reduce healthcare disparities while expanding the market reach.

In conclusion, these trends present strategic growth prospects that are driving innovation within various medical specialties, particularly radiography. By addressing diverse healthcare needs, the market can achieve sustainable growth and have a broader impact on global health.

Radiotheranostic Market Driver and Challenges

Various technological, economic, and regulatory factors affect the radiotheranostics market. Understanding these drivers and challenges is essential for navigating the market successfully and achieving sustainable growth.

The factors responsible for driving the radiotheranostic market include:

1. Technological Advancements: Innovations in radiation therapeutics production techniques, imaging methods, and targeted therapies have enhanced their effectiveness, stimulating market expansion.

2. Rising Cancer Incidence: The global increase in cancer cases demands more target-oriented therapies like radiotherapy, resulting in larger markets for radioisotopes used in this area.

3. Government Support: Increasing government assistance for the promotion of nuclear medicine and precision oncology through regulatory incentives and financing is boosting the growth of the radiotheranostics industry.

4. Globalization of Healthcare: Global healthcare collaborations have opened up access to radiotheranostics therapies, especially in developing nations.

5. Patient Demand for Personalized Medicine: Growing patient demand for personalized, minimally invasive treatments is driving the adoption of radiotheranostics, which offer tailored therapeutic options.

Challenges in the radiotheranostic market include:

1. Expensive Production Costs: The high cost of producing radioisotopes and developing radiotheranostics agents can limit affordability and access, posing a challenge to market growth.

2. Obstacles in Approvals: Stringent regulatory requirements for approval and the safe handling of radioactive materials can delay the introduction of new therapies.

3. Supply Chain Challenges: These include short half-life periods and limited production facilities, creating the potential for shortages and leading to treatment unavailability.

In conclusion, the radiotheranostics market is driven by technological advancements and the rising demand for personalized medicine, while facing challenges such as high production costs and regulatory hurdles. Successfully navigating these factors is essential for market players to achieve sustainable growth and deliver innovative treatments to patients.

List of Radiotheranostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiotheranostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiotheranostic companies profiled in this report include-

• Novartis
• Bayer
• Progenics Pharmaceuticals
• Telix Pharmaceuticals Limited
• ITM Radiopharma
• Life Molecular Imaging
• RadioMedix

Radiotheranostic by Segment

The study includes a forecast for the global radiotheranostic by radioisotope, approach, application, and region.

Radiotheranostic Market by Radioisotope [Analysis by Value from 2018 to 2030]:

• Iodine-131
• Iodine-123
• Gallium-68
• Lutetium-177
• 18F With Y-90
• Others

Radiotheranostic Market by Approach [Analysis by Value from 2018 to 2030]:

• Targeted Therapeutic
• Targeted Diagnostic

Radiotheranostic Market by Application [Analysis by Value from 2018 to 2030]:

• Oncology
• Non-Oncology

Radiotheranostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radiotheranostic Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by major radiotheranostics producers in key regions: the USA, China, India, Japan, and Germany:

• United States: The FDA has approved several radiotheranostics therapies for prostate cancer and neuroendocrine tumors, among others. This has been made possible by increasing funding in research and academic-industry partnerships that foster the development of next-generation radiotheranostics.
• China: China's investment in its nuclear medicine infrastructure includes the domestic production of radioisotopes. Recently, the country has established centers for radiotheranostics therapies through collaborations with global firms, meeting the rising demand for precise oncology care delivery.
• Germany: Institutions like the Deutsches Krebsforschungszentrum (German Cancer Research Center) have taken leadership roles in conducting clinical trials for new agents used in radiotheranostics. The country is also improving its regulatory framework to expedite patient access to modern treatments.
• India: Government-driven initiatives aimed at enhancing nuclear medicine capabilities are positioning India as a key player in the growing radiotheranostics domain. Recent developments include affordable radiotheranostics solutions and collaborations with overseas partners to boost technical know-how.
• Japan: Japan has seen progress in radioisotope production and distribution, among other developments, all aimed at integrating radiotheranostics into personalized medicine. Government support for research and the development of novel radiotheranostics agents is driving market growth, particularly in oncology.

Features of the Global Radiotheranostic Market

Market Size Estimates: Radiotheranostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiotheranostic market size by radioisotope, approach, application, and region in terms of value ($B).

Regional Analysis: Radiotheranostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotope, approaches, applications, and regions for the radiotheranostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiotheranostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radiotheranostic market by radioisotope (iodine-131, iodine-123, gallium-68, lutetium-177, 18F with Y-90, and others), approach (targeted therapeutic and targeted diagnostic), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiotheranostic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radiotheranostic Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radiotheranostic Market by Radioisotope
  • 3.3.1: Iodine-131
  • 3.3.2: Iodine-123
  • 3.3.3: Gallium-68
  • 3.3.4: Lutetium-177
  • 3.3.5: 18F with Y-90
  • 3.3.6: Others
• 3.4: Global Radiotheranostic Market by Approach
  • 3.4.1: Targeted Therapeutic
  • 3.4.2: Targeted Diagnostic
• 3.5: Global Radiotheranostic Market by Application
  • 3.5.1: Oncology
  • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radiotheranostic Market by Region
• 4.2: North American Radiotheranostic Market
  • 4.2.1: North American Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.2.2: North American Market by Application: Oncology and Non-oncology
• 4.3: European Radiotheranostic Market
  • 4.3.1: European Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.3.2: European Market by Application: Oncology and Non-oncology
• 4.4: APAC Radiotheranostic Market
  • 4.4.1: APAC Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.4.2: APAC Market by Application: Oncology and Non-oncology
• 4.5: ROW Radiotheranostic Market
  • 4.5.1: ROW Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.5.2: ROW Market by Application: Oncology and Non-oncology

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radiotheranostic Market by Radioisotope
  • 6.1.2: Growth Opportunities for the Global Radiotheranostic Market by Approach
  • 6.1.3: Growth Opportunities for the Global Radiotheranostic Market by Application
  • 6.1.4: Growth Opportunities for the Global Radiotheranostic Market by Region
• 6.2: Emerging Trends in the Global Radiotheranostic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radiotheranostic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiotheranostic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: Bayer
• 7.3: Progenics Pharmaceuticals
• 7.4: Telix Pharmaceuticals Limited
• 7.5: ITM Radiopharma
• 7.6: Life Molecular Imaging
• 7.7: RadioMedix